Rocket Lab's Launch Cadence Keeps Rolling While the Stock Takes a Breather

Rocket Lab's 94th Electron launch and IMM Apex solar cell production contrast with a 24% 30-day share slide; ARK buys while CFO sells under a 10b5-1 plan.

Rocket Lab's operational machine keeps humming even as its share price heads in the opposite direction. The company notched its 94th Electron launch and its 15th mission of 2026, lifting Synspective's StriX satellite into a 575-kilometer low Earth orbit from Launch Complex 1 in New Zealand. The mission, dubbed "Owl Around the World," departed on September 2 — a detail worth pinning down, since the company's German-language coverage has placed the same flight on both sides of the international date line. Either way, the cadence speaks for itself: this is a launch program that doesn't pause for market turbulence.

For Synspective alone, Rocket Lab has 16 more flights booked through 2030. That kind of backlog is the stuff most industrial firms can only dream about.

A Second Leg Built on Silicon, Not Just Rockets

Rocket Lab has spent years shedding the "mere rocket builder" label. Early September brought the production green light for IMM Apex, a new space-grade solar cell that delivers 31.5 percent conversion efficiency at the beginning of its life while weighing 40 percent less than its predecessors. The cell is germanium-free — a deliberate design choice that management framed as reducing reliance on scarce critical minerals — and it slots into existing systems as both a mechanical and electrical drop-in replacement.

These components ship to satellite manufacturers worldwide, regardless of whose rocket ultimately carries the payload. That's the strategic wager in a nutshell: Rocket Lab wants to shape the industry's infrastructure, not just fly for it.

Analysts Split on the Price Tag, United on the Rating

Berenberg initiated coverage on September 2 with a Buy rating and an $83 price target, citing vertically integrated launch capacity paired with a differentiated capability for sovereign satellite constellations. Bank of America had trimmed its own target shortly before, cutting from $115 to $110 while keeping its Buy recommendation — a sign that even bullish houses are recalibrating valuations after the recent slide.

The Chart Tells a Rougher Story

The stock changed hands at EUR 53.40 on Thursday, down roughly 24 percent over 30 days. Against the 52-week high of EUR 133.80 reached in late May, that's a 60 percent gap. Some market watchers put the 30-day decline nearer 22 percent and the year-to-date loss around 12 percent, though the 12-month picture still shows a gain of about 37 percent — a reminder of just how volatile this name can be.

What makes the selloff interesting is who's buying and who's selling into it.

ARK Investment Management, never shy about disruptive-technology bets, picked up roughly 681,000 Rocket Lab shares across two days in late August and early September. One market observer pegged ARK's single-day purchase on September 2 at 480,800 shares. Either way, it reads as a clear vote for the long-term thesis.

On the other side of the ledger, CFO Adam C. Spice exercised employee options on 140,157 shares at $1.09 apiece on September 2 and sold the same quantity that day at weighted average prices of $62.26 and $62.97. Another account puts the weighted average at $62.63, valuing the transaction at roughly $8.8 million. The sale ran through a Rule 10b5-1 trading plan established in June 2026 — a pre-arranged, automated mechanism designed to remove discretion from the decision. Spice still holds about 1.4 million shares directly, with another 250,000 held indirectly through a trust, so his interests remain substantially tied to the company.

Is there a contradiction between institutional buyers on one side and a selling executive on the other? Not necessarily. Plan-based insider sales say little about a company's future, while ARK's accumulation suggests the current weakness is being read as an entry point.

The Real Question Hiding Behind the Headlines

What all these individual data points obscure is a more fundamental issue: how much patience will the market extend to a company that delivers operationally but whose long-term bets — sovereign satellite infrastructure, the Neutron launch vehicle — have yet to pay off?

Rocket Lab stands as a case study for an entire slice of the New Space industry, navigating between technological maturity and capital-market patience. The answer won't come from the next analyst note. It'll come from the quarters of operational execution ahead.

Measured against its operational progress rather than its recent chart, Rocket Lab looks considerably healthier than the current quote suggests. The massive discount to the annual high reflects a broader risk aversion toward high-growth, thin-margin space stocks more than any company-specific problem.